The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice

A. Mcnamara (South San Francisco, United States of America), C. Campbell (South San Francisco, United States of America), A. Heinichen (South San Francisco, United States of America), E. Situ (South San Francisco, United States of America), W. Lee (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America)

Source: International Congress 2019 – Novel targets and mechanisms in asthma
Session: Novel targets and mechanisms in asthma
Session type: Oral Presentation
Number: 4952

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Mcnamara (South San Francisco, United States of America), C. Campbell (South San Francisco, United States of America), A. Heinichen (South San Francisco, United States of America), E. Situ (South San Francisco, United States of America), W. Lee (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America). The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice. 4952

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: